TG Therapeutics Inc - ESG Rating & Company Profile powered by AI
This analysis of TG Therapeutics Inc employs data from across the internet and also from public documents by TG Therapeutics Inc. If you work at TG Therapeutics Inc and you would like to licence your ESG aseessment, please contact us. This assessment of TG Therapeutics Inc is prepared by All Street Sevva using cutting edge artificial intelligence.
TG Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.2; made up of an environmental score of 1.3, social score of 1.1 and governance score of 1.3.
1.2
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1755 | TRACON Pharmaceuticals Inc | 1.3 | Low |
| 1755 | Trimurthi Ltd | 1.3 | Low |
| 1779 | TG Therapeutics Inc | 1.2 | Low |
| 1779 | Cell Biotech Co Ltd | 1.2 | Low |
| 1779 | Aurisco Pharmaceutical Co Ltd | 1.2 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does TG Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes TG Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes TG Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes TG Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes TG Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes TG Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes TG Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes TG Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes TG Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes TG Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes TG Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes TG Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes TG Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes TG Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes TG Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes TG Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes TG Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid TG Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes TG Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes TG Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas TG Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes TG Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes TG Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes TG Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes TG Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes TG Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes TG Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes TG Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs TG Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes TG Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes TG Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes TG Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes TG Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes TG Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes TG Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes TG Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for TG Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.